Biomaxima (BMX) - Net Assets
Based on the latest financial reports, Biomaxima (BMX) has net assets worth zł46.81 Million PLN (≈ $12.88 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (zł77.32 Million ≈ $21.28 Million USD) and total liabilities (zł30.50 Million ≈ $8.39 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check tangible net worth ratio of Biomaxima to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | zł46.81 Million |
| % of Total Assets | 60.55% |
| Annual Growth Rate | 19.68% |
| 5-Year Change | 82.43% |
| 10-Year Change | 202.62% |
| Growth Volatility | 34.93 |
Biomaxima - Net Assets Trend (2009–2024)
This chart illustrates how Biomaxima's net assets have evolved over time, based on quarterly financial data. See Biomaxima liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Biomaxima (2009–2024)
The table below shows the annual net assets of Biomaxima from 2009 to 2024. For live valuation and market cap data, see BMX market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | zł47.33 Million ≈ $13.02 Million |
+0.75% |
| 2023-12-31 | zł46.97 Million ≈ $12.93 Million |
-10.45% |
| 2022-12-31 | zł52.46 Million ≈ $14.44 Million |
+79.69% |
| 2021-12-31 | zł29.19 Million ≈ $8.03 Million |
+12.53% |
| 2020-12-31 | zł25.94 Million ≈ $7.14 Million |
+57.64% |
| 2019-12-31 | zł16.46 Million ≈ $4.53 Million |
-2.33% |
| 2018-12-31 | zł16.85 Million ≈ $4.64 Million |
-3.02% |
| 2017-12-31 | zł17.37 Million ≈ $4.78 Million |
+3.22% |
| 2016-12-31 | zł16.83 Million ≈ $4.63 Million |
+7.63% |
| 2015-12-31 | zł15.64 Million ≈ $4.30 Million |
+7.94% |
| 2014-12-31 | zł14.49 Million ≈ $3.99 Million |
+0.79% |
| 2013-12-31 | zł14.37 Million ≈ $3.96 Million |
+11.93% |
| 2012-12-31 | zł12.84 Million ≈ $3.53 Million |
+63.66% |
| 2011-12-31 | zł7.85 Million ≈ $2.16 Million |
+16.57% |
| 2010-12-31 | zł6.73 Million ≈ $1.85 Million |
+110.70% |
| 2009-12-31 | zł3.20 Million ≈ $879.33K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Biomaxima's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 5336.1% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | zł33.18 Million | 70.11% |
| Common Stock | zł4.19 Million | 8.86% |
| Other Comprehensive Income | zł112.00K | 0.24% |
| Other Components | zł9.84 Million | 20.79% |
| Total Equity | zł47.33 Million | 100.00% |
Biomaxima Competitors by Market Cap
The table below lists competitors of Biomaxima ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Star Combo Pharma Ltd
AU:S66
|
$10.99 Million |
|
Megapolitan Developments Tbk
JK:EMDE
|
$10.99 Million |
|
Globe Textiles (India) Limited
NSE:GLOBE
|
$11.01 Million |
|
Mitra Pemuda Tbk PT
JK:MTRA
|
$11.01 Million |
|
Karnalyte Resources Inc.
TO:KRN
|
$10.99 Million |
|
Cofidur SA
PA:ALCOF
|
$10.97 Million |
|
Kier Group PLC
LSE:KIE
|
$10.97 Million |
|
GreenOak Spain Holdings SOCIMI S.A.
MC:YGO2
|
$10.95 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Biomaxima's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 46,974,000 to 47,326,000, a change of 352,000 (0.7%).
- Net income of 535,000 contributed positively to equity growth.
- Other comprehensive income increased equity by 17,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | zł535.00K | +1.13% |
| Other Comprehensive Income | zł17.00K | +0.04% |
| Other Changes | zł-200.00K | -0.42% |
| Total Change | zł- | 0.75% |
Book Value vs Market Value Analysis
This analysis compares Biomaxima's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.84x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 6.06x to 0.84x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2009-12-31 | zł1.57 | zł9.52 | x |
| 2010-12-31 | zł3.25 | zł9.52 | x |
| 2011-12-31 | zł3.85 | zł9.52 | x |
| 2012-12-31 | zł4.22 | zł9.52 | x |
| 2013-12-31 | zł4.73 | zł9.52 | x |
| 2014-12-31 | zł4.77 | zł9.52 | x |
| 2015-12-31 | zł5.14 | zł9.52 | x |
| 2016-12-31 | zł4.51 | zł9.52 | x |
| 2017-12-31 | zł4.64 | zł9.52 | x |
| 2018-12-31 | zł4.49 | zł9.52 | x |
| 2019-12-31 | zł4.40 | zł9.52 | x |
| 2020-12-31 | zł4.63 | zł9.52 | x |
| 2021-12-31 | zł6.51 | zł9.52 | x |
| 2022-12-31 | zł11.76 | zł9.52 | x |
| 2023-12-31 | zł10.88 | zł9.52 | x |
| 2024-12-31 | zł11.29 | zł9.52 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Biomaxima utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 1.13%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 1.01%
- • Asset Turnover: 0.69x
- • Equity Multiplier: 1.61x
- Recent ROE (1.13%) is below the historical average (13.35%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2009 | 19.10% | 9.15% | 1.16x | 1.80x | zł290.86K |
| 2010 | 8.01% | 7.52% | 0.68x | 1.56x | zł-134.17K |
| 2011 | 12.73% | 9.52% | 0.80x | 1.67x | zł214.20K |
| 2012 | 10.71% | 7.31% | 0.97x | 1.52x | zł90.74K |
| 2013 | 9.19% | 6.30% | 0.93x | 1.57x | zł-117.13K |
| 2014 | 3.14% | 2.23% | 0.95x | 1.48x | zł-993.99K |
| 2015 | 9.30% | 6.62% | 1.00x | 1.40x | zł-109.15K |
| 2016 | 7.29% | 4.55% | 1.15x | 1.39x | zł-455.57K |
| 2017 | 4.66% | 2.55% | 1.16x | 1.58x | zł-923.82K |
| 2018 | -2.88% | -1.56% | 0.70x | 2.62x | zł-2.16 Million |
| 2019 | -0.08% | -0.04% | 0.70x | 2.64x | zł-1.66 Million |
| 2020 | 39.97% | 12.90% | 1.15x | 2.69x | zł5.96 Million |
| 2021 | 35.09% | 12.95% | 1.28x | 2.12x | zł7.32 Million |
| 2022 | 55.07% | 20.08% | 1.93x | 1.42x | zł23.64 Million |
| 2023 | 1.25% | 1.25% | 0.63x | 1.57x | zł-4.11 Million |
| 2024 | 1.13% | 1.01% | 0.69x | 1.61x | zł-4.20 Million |
Industry Comparison
This section compares Biomaxima's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $137,024,291
- Average return on equity (ROE) among peers: -1.79%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Biomaxima (BMX) | zł46.81 Million | 19.10% | 0.65x | $10.99 Million |
| Scope Fluidics SA (SCP) | $6.70 Million | -9.52% | 0.41x | $91.68 Million |
| Selvita S.A. (SLV) | $321.73 Million | 0.25% | 0.86x | $156.57 Million |
| Voxel S.A. (VOX) | $82.64 Million | 3.88% | 1.03x | $341.08 Million |
About Biomaxima
BioMaxima S.A. produces and distributes microbiological media, reagents, and in vitro diagnostic equipment in Poland. It offers microbiology products, including ready to use media, such as plates, bottles, bags, and media in tubes; dehydrated media; agars and peptones; and supplements. The company also provides molecular biology and cell culture products which includes real time PCR, nucleic acid… Read more